Updated daily
Drug recalls
Every FDA drug recall since 2004 - 18,109 enforcement reports, newest first, with what was recalled, why, the lots and the company. Class I is the most serious.
Class ITerminatedFeb 1, 2023Advil (ibuprofen) TabletsLabeling: Illegible Label; the adhesive migrated onto a portion of the label, causing it to tear when peeled backGlaxosmithkline Consumer Healthcare Holdings DBA Haleon · D-0181-2023Class ITerminatedFeb 1, 2023EpinephrineDiscoloration: Product complaints of the repackaged Epinephrine API being discolored which could result in less effective productSpectrum Laboratory Products, Inc. · D-0180-2023Class ITerminatedFeb 1, 2023EpinephrineDiscoloration: Product complaints of the repackaged Epinephrine API being discolored which could result in less effective productSpectrum Laboratory Products, Inc. · D-0179-2023Class IITerminatedFeb 1, 2023Sterile Water for InjectionCGMP Deviations: potential for trace amounts of product carryover.Nephron Sc Inc · D-0178-2023Class IITerminatedFeb 1, 20230.9% Sodium Chloride InjectionCGMP Deviations: potential for trace amounts of product carryover.Nephron Sc Inc · D-0177-2023Class IITerminatedFeb 1, 2023S2 Racepinephrine Inhalation SolutionShort FillNephron Sc Inc · D-0176-2023Class IITerminatedFeb 1, 2023Asthmanefrin Racepinephrine Inhalation Solution BronchodilatorShort FillNephron Sc Inc · D-0175-2023Class IIITerminatedFeb 1, 2023Clobetasol propionate Cream USPSubpotent Drug: Low assay result observed during long-term stability testing.Lupin Pharmaceuticals Inc. · D-0174-2023Class IITerminatedFeb 1, 2023Allopurinol Tablets 100mgPresence of Foreign Substance: manufacturer recalled this re-packaged product due to reports of a small piece of green plastic embedded in the crack towards the edge of...Preferred Pharmaceuticals, Inc. · D-0173-2023Class IIITerminatedFeb 1, 2023FentaNYL Citrate 2.5mg/50mLShort Fill: Underfilled units.OurPharma LLC · D-0172-2023Class IITerminatedFeb 1, 2023Metoprolol Succinate Extended-Release TabletsFailed Dissolution SpecificationAscend Laboratories, LLC · D-0171-2023Class IITerminatedFeb 1, 2023Metoprolol Succinate Extended-Release TabletsFailed Dissolution SpecificationAscend Laboratories, LLC · D-0170-2023Class IITerminatedFeb 1, 2023Metoprolol Succinate Extended-Release TabletsFailed Dissolution SpecificationAscend Laboratories, LLC · D-0169-2023Class IITerminatedFeb 1, 2023Allopurinol Tablets USPPresence of Foreign Substance: Presence of a small piece of green plastic embedded in the crack towards the edge of the tablet.Accord Healthcare, Inc. · D-0168-2023Class IIITerminatedJan 25, 2023SINUVA (mometasone furoate) sinus implantFailed Dissolution Specification; product did not meet the average 24-hour drug release rate (dissolution) specification stability time point at 9 months.Intersect ENT, Inc. · D-0167-2023Class IIOngoingJan 25, 2023SIREtizer Hand SanitizerCGMP Deviations and Superpotent Drug: Levels of acetal and acetaldehyde above allowable limits. Additionally, lot 001 was superpotent.Southwest Iowa Renewable Energy LLC · D-0166-2023Class IITerminatedJan 25, 2023Rifampin Capsules USPFailed Impurities/Degradations SpecificationsAmerisource Health Services LLC · D-0165-2023Class IIOngoingJan 25, 2023Hand SanitizerCGMP Deviations: Voluntary recall of all hand sanitizer distributed after March 31, 2022, due to FDA issued guidance to cease placing hand sanitizer product, produced...Fisher Scientific Co., LLC · D-0164-2023Class IIOngoingJan 25, 2023Hand SanitizerCGMP Deviations: Voluntary recall of all hand sanitizer distributed after March 31, 2022, due to FDA issued guidance to cease placing hand sanitizer product, produced...Fisher Scientific Co., LLC · D-0163-2023Class IIITerminatedJan 25, 2023Levofloxacin TabletsMismatching of the embossing on the tablets (T7) with the embossing mentioned in the package insert (ML63) in the distributed bottles.Macleods Pharma USA, Inc · D-0162-2023Class IIITerminatedJan 25, 2023Triamterene and Hydrochlorothiazide CapsulesFailed Impurity/Degradation SpecificationsLannett Company Inc. · D-0161-2023Class IIITerminatedJan 25, 2023Triamterene and Hydrochlorothiazide CapsulesFailed Impurity/Degradation SpecificationsLannett Company Inc. · D-0160-2023Class IITerminatedJan 25, 2023Rasagiline Mesylate Tablets 1 mgPresence of Foreign Substance- A complaint was received of black spots/shiny metallic speck on the tablets.Ascend Laboratories, LLC · D-0159-2023Class IIOngoingJan 25, 2023Tobramycin Ophthalmic SolutionCGMP Deviations:Akorn, Inc. · D-0158-2023Class IIOngoingJan 25, 2023Tobramycin Ophthalmic SolutionCGMP Deviations:Akorn, Inc. · D-0157-2023Class IIOngoingJan 25, 2023Timolol Maleate Ophthalmic SolutionCGMP Deviations:Akorn, Inc. · D-0156-2023Class IIOngoingJan 25, 2023Sodium Chloride Ophthalmic OintmentCGMP Deviations:Akorn, Inc. · D-0155-2023Class IIOngoingJan 25, 2023Proparacaine Hydrochloride Ophthalmic SolutionCGMP Deviations:Akorn, Inc. · D-0154-2023Class IIOngoingJan 25, 2023Proparacaine Hydrochloride Ophthalmic SolutionCGMP Deviations:Akorn, Inc. · D-0153-2023Class IIOngoingJan 25, 2023PAREMYDCGMP Deviations:Akorn, Inc. · D-0152-2023Class IIOngoingJan 25, 2023Olopatadine HCl Ophthalmic SolutionCGMP Deviations:Akorn, Inc. · D-0151-2023Class IIOngoingJan 25, 2023Olopatadine HCl Ophthalmic SolutionCGMP Deviations:Akorn, Inc. · D-0150-2023Class IIOngoingJan 25, 2023Olopatadine HCl Ophthalmic SolutionCGMP Deviations:Akorn, Inc. · D-0149-2023Class IIOngoingJan 25, 2023Olopatadine HCL Ophthalmic SolutionCGMP Deviations:Akorn, Inc. · D-0148-2023Class IIOngoingJan 25, 2023Olopatadine HCl Ophthalmic SolutionCGMP Deviations:Akorn, Inc. · D-0147-2023Class IIOngoingJan 25, 2023Ofloxacin Ophthalmic SolutionCGMP Deviations:Akorn, Inc. · D-0146-2023Class IIOngoingJan 25, 2023Neomycin and Polymyxin B SulfatesCGMP Deviations:Akorn, Inc. · D-0145-2023Class IIOngoingJan 25, 2023Moxifloxacin Ophthalmic SolutionCGMP Deviations:Akorn, Inc. · D-0144-2023Class IIOngoingJan 25, 2023Lidocaine Hydrochloride Jelly USPCGMP Deviations:Akorn, Inc. · D-0143-2023Class IIOngoingJan 25, 2023Levofloxacin Ophthalmic Solution 0.5%CGMP Deviations:Akorn, Inc. · D-0142-2023